Zymeworks Inc.

Overview

Zymeworks Inc. is a biotechnology company based in Vancouver, British Columbia, that specializes in developing protein therapeutics for cancer, autoimmune diseases, and inflammatory conditions. Founded in 2003, it went public in May 2017 and has since focused on creating multifunctional biotherapeutics using proprietary molecular modeling software and protein engineering platforms.

With key platforms such as Azymetric™ for bispecific antibodies and EFECT™ for multi-specific antibodies, Zymeworks' lead product Ziihera® (zanidatamab-hrii) is a HER2-targeted bispecific antibody currently in clinical trials. Strategic partnerships with major organizations like Merck and GSK enhance its development capabilities and validate its technology. The company aims to optimize its healthcare asset portfolio while supporting the development of innovative medicines.

Basic Information

Contact Details

• Phone: +1 604-678-1388
• Website: zymeworks.com
• LinkedIn: linkedin.com/company/zymeworks

Key Focus Areas & Initiatives

• antibody therapeutics
• bispecific antibodies
• effector function modulation
• adc
• breast cancer
• gastric cancer
• protein engineering
• immune redirection
• biliary tract cancer
• biotechnology
• life sciences
• biotechnology: pharmaceutical preparations
• health care
• biotechnology research
• health, wellness & fitness

Technologies Used

• Atlassian Cloud
• Bootstrap Framework
• DNS Made Easy
• Drupal
• Google Analytics
• Google Font API
• Google Tag Manager
• Gravity Forms
• MailChimp SPF
• Mapbox
• Microsoft Office 365
• Mobile Friendly
• Nginx
• Outlook
• Remote
• Sophos
• Varnish
• WordPress.org
• reCAPTCHA

Affiliated Organizations & Regional Branches

• Kairos Therapeutics